Related Experiment Videos
[Therapeutic possibilities in terminal heart failure]
1Klinik für Innere Medizin, Bereich Medizin der Wilhelm-Pieck-Universität Rostock.
Insights
Severe cardiac insufficiency presents challenges, with current treatments offering only temporary stabilization and failing to correct underlying neurohumoral dysregulation. Cardiac transplantation remains the primary alternative for improved cardiovascular function.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Severe and terminal cardiac insufficiency, characterized by myogenic failure and neurohumoral dysregulation, poses significant clinical challenges in both chronic and acute forms.
- Current therapeutic strategies involve basic treatments with glycosides and saluretics, often augmented by vasodilators or adrenergic agonists to stabilize the cardiovascular system.
Purpose:
- To evaluate the efficacy of existing and novel pharmacological interventions in managing severe cardiac insufficiency.
- To assess the potential of new inotropic and vasodilating agents in altering the prognosis of cardiac insufficiency.
- To review alternative treatment options, including cardiac transplantation and mechanical circulatory support systems.
Summary:
- Medicamentous treatment can temporarily stabilize cardiovascular function but does not resolve persistent neurohumoral dysregulation, perpetuating a cycle of decline.
- The long-term impact of novel inotropic and vasodilating pharmaceuticals on cardiac and vascular dysfunction, as well as neurohumoral imbalances, remains uncertain.
- Cardiac transplantation offers a distinct alternative for improving cardiovascular function, while artificial hearts and ventricular assist devices serve as temporary measures.
Impact:
- Current medical treatments provide limited improvement in maximum stress tolerance and do not address the fundamental neurohumoral dysregulation.
- Cardiac transplantation represents a definitive therapeutic option, though challenges remain with mechanical circulatory support systems.
- Further research is needed to determine if new pharmacological agents can significantly alter the prognosis for patients with severe cardiac insufficiency.
Abstract:
The severe and terminal cardiac insufficiency with myogenic failure and severe neurohumoral dysregulation means a problem situation in the chronically progressive or acute form of the course. The medicamentous treatment in form of the basis therapy with glycosides and saluretics may be improved by vasodilators or/and adrenergic agonists. In most cases we succeed in stabilizing the cardiovascular situation once to several times. As a rule the maximum stress only little increases. The neurohumoral dysregulation remains in different form apart from the basic disease which is no more to be corrected. Thus, in principle the vicious circle is closed. Whether the group of the so-called new inotropic and vasodilating pharmaca may essentially change the prognosis due to better influences on cardial and vascular and neurohumoral, respectively, dysfunctions, is not yet to be answered. A distinct alternative from the aspect of the cardiovascular function gives only the cardiac transplantation. The artificial heart and ventricular assist-systems, respectively, are accepted for the bridging-over up to the cardiac transplantation. The hitherto existing state of development does not yet correspond to the imaginations of a pump regulated according to the needs, disregarding material, coagulation and energy problems.